Literature DB >> 24334643

Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.

Vivian P Bykerk1, Nancy Shadick, Michelle Frits, Clifton O Bingham, Iain Jeffery, Christine Iannaccone, Michael Weinblatt, Daniel H Solomon.   

Abstract

OBJECTIVE: To describe the frequency, duration, and management of flares as reported by patients with rheumatoid arthritis (RA).
METHODS: Data were collected in a prospective observational study of patients with RA recruited from a single academic center and treated according to the rheumatologists' discretion. Every 6 months, patients reported the number and duration of RA flares and described how these were managed in terms of adding or changing medication and use of nonpharmacologic strategies.
RESULTS: Of patients who reported flares at least once during the study, 74% reported having flares 6 months prior to study entry and 59% reported flares prior to the first 6-month visit. At subsequent visits, 54-57% reported having > 1 flare. Thirty percent of patients in remission reported flares. Flare duration lasted ≥ 2 weeks in 30%, 1-2 weeks in 13%, and < 1 week in 57%. Forty percent reported medication changes at the time of their flare; 16% changed medication and used nonpharmacologic strategies and 26% of patients reported no changes in treatment as a result of flares. Longer duration of flare was associated with changes in disease-modifying therapy.
CONCLUSION: Patients with RA experienced flares more often when noted to be in higher disease activity states than when in remission and reported changes in disease-modifying antirheumatic drugs or biologics more frequently when flares were of longer duration. There is a need to prospectively study symptom intensity and duration of flare in relation to disease activity and consider self-management strategies in the development of a measure of flare.

Entities:  

Keywords:  DISEASE MANAGEMENT; DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; FLARES; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2013        PMID: 24334643     DOI: 10.3899/jrheum.121521

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  24 in total

1.  Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease.

Authors:  Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-16       Impact factor: 4.794

2.  Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Authors:  Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

3.  Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.

Authors:  Katie Bechman; Lieke Tweehuysen; Toby Garrood; David L Scott; Andrew P Cope; James B Galloway; Margaret H Y Ma
Journal:  J Rheumatol       Date:  2018-09-01       Impact factor: 4.666

4.  Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trial.

Authors:  Elena Myasoedova; Cynthia S Crowson; Rachel E Giblon; Kathleen McCarthy-Fruin; Daniel E Schaffer; Kerry Wright; Eric L Matteson; John M Davis
Journal:  Clin Rheumatol       Date:  2019-07-01       Impact factor: 2.980

5.  Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.

Authors:  Lisa G Rider; Christine G Parks; Jesse Wilkerson; Adam I Schiffenbauer; Richard K Kwok; Payam Noroozi Farhadi; Sarvar Nazir; Rebecca Ritter; Emily Sirotich; Kevin Kennedy; Maggie J Larche; Mitchell Levine; Sebastian E Sattui; Jean W Liew; Carly O Harrison; Tarin T Moni; Aubrey K Miller; Michael Putman; Jonathan Hausmann; Julia F Simard; Jeffrey A Sparks; Frederick W Miller
Journal:  Rheumatology (Oxford)       Date:  2022-06-28       Impact factor: 7.046

Review 6.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

Review 7.  Is There a Role for Diet in the Therapy of Rheumatoid Arthritis?

Authors:  Sara K Tedeschi; Karen H Costenbader
Journal:  Curr Rheumatol Rep       Date:  2016-05       Impact factor: 4.592

8.  Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Irina A Tikhonova; Huiqin Yang; Segun Bello; Andrew Salmon; Sophie Robinson; Mohsen Rezaei Hemami; Sophie Dodman; Andriy Kharechko; Richard C Haigh; Meghna Jani; Timothy J McDonald; Martin Hoyle
Journal:  Health Technol Assess       Date:  2021-02       Impact factor: 4.014

9.  Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial.

Authors:  Yvonne C Lee; Fengxin Lu; Joshua Colls; Dee Luo; Penny Wang; Dorothy D Dunlop; Lutfiyya N Muhammad; Jing Song; Kaleb Michaud; Daniel H Solomon
Journal:  Arthritis Rheumatol       Date:  2021-06-18       Impact factor: 15.483

10.  Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.

Authors:  Iris M Markusse; Linda Dirven; Andreas H Gerards; Johannes H L M van Groenendael; H Karel Ronday; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart
Journal:  Arthritis Res Ther       Date:  2015-08-31       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.